**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number

10/634,706

Filing Date

August 4, 2003

First Named Inventor

Annis, Gary D.

Group Art Unit

Unassigned

Examiner Name

Unassigned

Total Number of Pages in This Submission

Attorney Docket Number

407J-000441US

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	USPTO Form 1449 (copy from Parent); receipt acknowledgment postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENTFirm
or
Individual name

Paul Littlepage, Reg. No. 48,581, Quine Intellectual Property Law Group, P.C.

Signature

Date

October 14, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name

Amelia Weintraub

Signature


Date

October 14, 2003



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on October 14, 2003

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By 
Amelia Weintraub

Attorney Docket No. 407J-000441US
Client Ref. No. 2003-036-5 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Annis, Gary D., et al.

Application No.: 10/634,706

Filed: August 4, 2003

For: Herbicidal Oxadiazolidines

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO-1449 form are being called to the attention of the Examiner to make of record references cited in parent application USSN 09/869,771 filed June 20, 2001. Pursuant to 37 CFR § 1.98(d), copies of references cited in parent application USSN 09/869,771 filed June 20, 2001 are not provided. However the applicants will gladly provide fresh copies of any references requested by the Examiner.


It is respectfully requested that the cited information on the attached 1449 form(s) be expressly considered during the prosecution of this application, and that references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Paul Littlepage
Reg. No. 48,581

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Please type a plus sign (+) inside this ... x

GOVERNMENT PRINTING OFFICE

PTO/SB/088 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/809,771 10/634,706
Filing Date	JUNE 29, 2004 Aug. 4, 2003
First Named Inventor	GARY DAVID ANNIS ET AL.
Group Art Unit	1616
Examiner Name	UNKNOWN
Attorney Docket Number	BA9238 US PET 4073-000441US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DATABASE CROSSFIRE Online - Beilstein Institut zur Foerderung der Chemischen Wissenschaften; XP002141082 Beilstein Registry Number 5973265, 5944839, 5942772, 5940606, 5927572 & Arch. Pharm., vol. 314, no. 4, 1981, pages 294-302	
		DATABASE CROSSFIRE Online - Beilstein Institut zur Foerderung der Chemischen Wissenschaften; XP992141083 Beilstein Registry Number 513318, 611515, 519232, 509077, 510600, 511401 & Arch. Pharm. Ber. DTSCH. Pharm. GES., vol. 303, 1970, pages 139-144	
		DATABASE CROSSFIRE Online Beilstein Institut zur Foerderung der Chemischen Wissenschaften; XP002141084 Beilstein Registry Number 972970, 973571, 974317, 975960, 981328 & Arch Pharm Ber. DTSCH. Pharm GES., vol. 303, 1970, pages 385-390	
		DATABASE CROSSFIRE Online Beilstein Institut zur Foerderung der Chemischen Wissenschaften; XP002141085 Beilstein Registry Number 519889, 521425, 522254, 534767, 4937992 & Chem. Ber., vol. 98, 1965, pages 144-154	
		CHEMICAL ABSTRACTS, vol. 80, no. 19, 13 May 1974 Columbus, Ohio, US; abstract no. 108148v, ZINNER G ET AL: "Hydroxylamine derivatives. 56. Synthesis and acylations of 1, 1-Dialkyl-3-hydroxyureas" page 383; XP002141164 cited in the application abstract & Arch. Pharm., vol. 307, no. 1, 1974, pages 7-12, Weinheim, DE	
		ARCH. PHARM (1974), 307, 7-12	x

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.